Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

NCT00813423 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm

Interventions

DRUG: Hydroxychloroquine
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Sunitinib Malate

Sponsor

National Cancer Institute (NCI)